Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
AssigneeThe Scripps Research Institute
InventorsTheo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
Life of this patent
Estimating the term…
Abstract
The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
Claims7
A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), but does not substantially inhibit LBP binding to LPS, wherein said monoclonal antibody has a binding specificity to LBP, to denatured LBP, and to a complex of LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 8C9, Mab 18G4, or Mab 24B7.
A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS, wherein said monoclonal antibody has a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.
A hybridoma cell line that produces a monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS, wherein said monoclonal antibody has a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS, and wherein said binding specificity is that of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.
Dependencies are inferred from the claim text.